Alzamend Neuro, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended October 31, 2023; the filing was signed December 15, 2023. The company is a clinical-stage biopharmaceutical developer with no product revenue. Financial statements are unaudited.
Business context and development
Alzamend’s pipeline comprises AL001, a lithium-based ionic cocrystal candidate being developed for Alzheimer’s disease and other indications, and ALZN002, an investigational cell-based immunotherapy vaccine for Alzheimer’s. The company says it is devoting substantially all efforts to research and development and raising capital.
- AL001 Phase IIA dosing for Alzheimer’s was completed in March 2023; the company announced positive topline data in June 2023. It reported FDA “study may proceed” letters for its bipolar disorder IND in September 2023 and its major depressive disorder IND in November 2023; the PTSD IND was filed in November 2023.
- ALZN002’s Phase I/IIA trial began in April 2023. The company described a planned 20–30-subject study, with a larger Phase IIB trial dependent on initial trial data.
Financial performance and position
| Metric | Three months ended October 31 | Six months ended October 31 |
|---|---|---|
| Revenue | None in 2023 or 2022 | None in 2023 or 2022 |
| Research and development expense | $2.00 million, up 30% | $4.36 million, up 50% |
| General and administrative expense | $0.90 million, down 42% | $2.06 million, down 36% |
| Total operating expenses | $2.90 million, down 7% | $6.43 million, up 5% |
| Net loss | $2.91 million, versus $3.11 million | $6.43 million, versus $6.15 million |
| Basic and diluted loss per share | $0.44, versus $0.48 | $0.98, versus $0.95 |
For the six-month period, clinical trial fees rose to $2.04 million from $0.58 million, primarily reflecting spending on both candidates. Lower stock-based compensation helped reduce G&A. No meaningful operating margin is available because the company had no revenue.
Cash was $200,079 at October 31, 2023, compared with $5.14 million at April 30, 2023. Six-month operating cash use was $4.81 million; investing cash use was $147,243, mainly for equipment for the ALZN002 trial; financing provided $18,087 from stock sales. The filing reports current liabilities of $3.67 million, all accounts payable and accrued liabilities, and a $2.88 million working-capital deficit. Total assets were $983,597 and stockholders’ deficit was $2.68 million. It reports no borrowings on the balance sheet; interest expense was $6,147 for the six months.
Material changes, funding and outlook
- Six-month net loss increased 5% year over year as higher R&D, particularly clinical-trial expense, more than offset lower G&A. The quarterly net loss improved 7% year over year.
- Management states cash on hand is insufficient to fund planned operations for one year after issuance of the financial statements. The filing identifies substantial doubt about the company’s ability to continue as a going concern and says additional funding is required. It warns that inability to raise capital could delay, reduce or eliminate development programs and trials.
- An at-the-market offering of up to approximately $9.8 million was established in September 2023. It generated $19,000 gross proceeds through October 31; from November 1 through December 14, the company sold 651,046 shares for $849,000 gross proceeds. Further equity or debt financing, warrant exercises and collection of a related-party note are cited as potential funding sources, not assured proceeds.
- The company expects continued losses and no product revenue for the foreseeable future. No quantified earnings or cash-flow guidance is provided.
- Nasdaq notified the company on September 26, 2023 that its market value of listed securities had been below the $35 million minimum for 30 consecutive business days. It had until March 25, 2024 to regain compliance; failure could lead to delisting, subject to appeal.
- A one-for-fifteen reverse stock split became effective October 31, 2023; share figures in the financial statements were adjusted retroactively. Subsequent to quarter-end, the company amended the ALZN002 license to modify license-fee payment timing.
Risks, contingencies and controls
- The company’s products remain investigational and require clinical, regulatory and funding progress before any commercialization or revenue. License agreements include royalties and milestone payments; missed specified milestones may permit the licensor to terminate licenses. Disclosed future milestones include, among others, a $1.25 million AL001 payment tied to first Phase III patient treatment and ALZN002 milestone payments tied to clinical progress and commercial sale.
- A related-party note receivable for common stock had an outstanding balance of $14.88 million at October 31, 2023, is secured by the purchased shares, and was scheduled to mature December 31, 2023. The filing does not establish that collection is assured. Certain company directors also serve as directors of entities in the related-party ownership chain.
- Management concluded internal control over financial reporting was ineffective because previously reported material weaknesses were not remediated. Identified issues include inadequate accounting-function resources and deficiencies in system access, segregation of duties and change-management controls. Remediation is ongoing.
- The company reported no legal proceedings believed likely to have a material adverse effect and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Cash runway, near-term cash needs and whether the company can secure financing on acceptable terms.
- ATM issuance pace, proceeds net of fees, dilution and compliance with Nasdaq’s market-value requirement.
- Collection status and any extension or other resolution of the $14.88 million related-party note receivable.
- Clinical-trial enrollment, timing and results for AL001 and ALZN002, and the regulatory status of the additional AL001 indications.
- Upcoming license milestones, amended payment terms, and progress remediating the reported material weaknesses.